Theravance Biopharma (TBPH) Competitors

Theravance Biopharma logo
$17.03 0.00 (0.00%)
As of 11/6/2026

TBPH vs. ARQT, INDV, SUPN, BHC, and MOR

Should you buy Theravance Biopharma stock or one of its competitors? Theravance Biopharma's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), Indivior (INDV), Supernus Pharmaceuticals (SUPN), Bausch Health Cos (BHC), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Theravance Biopharma (NASDAQ:TBPH) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

99.1% of Theravance Biopharma shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Theravance Biopharma currently has a consensus target price of $19.00, suggesting a potential upside of 11.57%. Arcutis Biotherapeutics has a consensus target price of $39.75, suggesting a potential upside of 40.66%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Arcutis Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

Theravance Biopharma has a net margin of 51.58% compared to Arcutis Biotherapeutics' net margin of 5.88%. Arcutis Biotherapeutics' return on equity of 14.18% beat Theravance Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Theravance Biopharma51.58% -0.77% -0.46%
Arcutis Biotherapeutics 5.88%14.18%6.28%

Theravance Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 2 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.61 beat Theravance Biopharma's score of 0.54 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcutis Biotherapeutics
1 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Theravance Biopharma has higher earnings, but lower revenue than Arcutis Biotherapeutics. Theravance Biopharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$104.31M8.48$105.89M$1.0116.86
Arcutis Biotherapeutics$508.68M7.03-$16.14M$0.21134.57

Summary

Arcutis Biotherapeutics beats Theravance Biopharma on 11 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Indivior?

Indivior (NASDAQ:INDV) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Theravance Biopharma has a net margin of 51.58% compared to Indivior's net margin of 32.75%. Theravance Biopharma's return on equity of -0.77% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior32.75% -418.04% 42.96%
Theravance Biopharma 51.58%-0.77%-0.46%

In the previous week, Indivior and Indivior both had 2 articles in the media. Indivior's average media sentiment score of 1.67 beat Theravance Biopharma's score of 0.54 indicating that Indivior is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Indivior
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Theravance Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Indivior has higher revenue and earnings than Theravance Biopharma. Indivior is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior$1.37B2.42$210M$3.587.88
Theravance Biopharma$104.31M8.48$105.89M$1.0116.86

Indivior currently has a consensus price target of $46.40, suggesting a potential upside of 64.48%. Theravance Biopharma has a consensus price target of $19.00, suggesting a potential upside of 11.57%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00
Theravance Biopharma
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Indivior has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

60.3% of Indivior shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Indivior beats Theravance Biopharma on 10 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Supernus Pharmaceuticals?

Theravance Biopharma (NASDAQ:TBPH) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Supernus Pharmaceuticals has higher revenue and earnings than Theravance Biopharma. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$104.31M8.48$105.89M$1.0116.86
Supernus Pharmaceuticals$1.24B2.83$210M$3.588.30

Theravance Biopharma has a net margin of 51.58% compared to Supernus Pharmaceuticals' net margin of 32.75%. Theravance Biopharma's return on equity of -0.77% beat Supernus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Theravance Biopharma51.58% -0.77% -0.46%
Supernus Pharmaceuticals 32.75%-418.04%42.96%

In the previous week, Supernus Pharmaceuticals had 6 more articles in the media than Theravance Biopharma. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 2 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.54 beat Supernus Pharmaceuticals' score of 0.48 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Supernus Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Theravance Biopharma currently has a consensus target price of $19.00, indicating a potential upside of 11.57%. Supernus Pharmaceuticals has a consensus target price of $60.20, indicating a potential upside of 102.56%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Supernus Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.71

Theravance Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

99.1% of Theravance Biopharma shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by insiders. Comparatively, 0.7% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Theravance Biopharma on 10 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to Bausch Health Cos?

Theravance Biopharma (NASDAQ:TBPH) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Theravance Biopharma has a net margin of 51.58% compared to Bausch Health Cos' net margin of -7.57%. Theravance Biopharma's return on equity of -0.77% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
Theravance Biopharma51.58% -0.77% -0.46%
Bausch Health Cos -7.57%-401.73%7.34%

In the previous week, Bausch Health Cos had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Bausch Health Cos and 2 mentions for Theravance Biopharma. Bausch Health Cos' average media sentiment score of 0.62 beat Theravance Biopharma's score of 0.54 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bausch Health Cos
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Theravance Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Theravance Biopharma presently has a consensus price target of $19.00, indicating a potential upside of 11.57%. Bausch Health Cos has a consensus price target of $8.75, indicating a potential upside of 4.73%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bausch Health Cos
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86

Bausch Health Cos has higher revenue and earnings than Theravance Biopharma. Bausch Health Cos is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$104.31M8.48$105.89M$1.0116.86
Bausch Health Cos$10.27B0.30$157M-$2.29N/A

Summary

Theravance Biopharma beats Bausch Health Cos on 8 of the 15 factors compared between the two stocks.

How does Theravance Biopharma compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Theravance Biopharma has a consensus price target of $19.00, indicating a potential upside of 11.57%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Theravance Biopharma
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Theravance Biopharma had 2 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Theravance Biopharma and 0 mentions for MorphoSys. Theravance Biopharma's average media sentiment score of 0.54 beat MorphoSys' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
MorphoSys Neutral
Theravance Biopharma Positive

Theravance Biopharma has a net margin of 51.58% compared to MorphoSys' net margin of -226.79%. Theravance Biopharma's return on equity of -0.77% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
MorphoSys-226.79% -694.31% -22.55%
Theravance Biopharma 51.58%-0.77%-0.46%

MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Theravance Biopharma has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$238.28M11.99-$205.35M-$3.48N/A
Theravance Biopharma$104.31M8.48$105.89M$1.0116.86

Summary

Theravance Biopharma beats MorphoSys on 12 of the 15 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TBPH vs. The Competition

MetricTheravance BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$884.18M$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E Ratio16.8626.0432.9127.37
Price / Sales8.487.318.595.73
Price / CashN/A15.7421.9322.50
Price / Book2.915.144.403.70
Net Income$105.89M$2.88B$3.52B$392.17M
7 Day PerformanceN/A-3.87%-5.34%-4.53%
1 Month PerformanceN/A-3.96%-3.61%-5.86%
1 Year Performance-2.07%-7.13%0.01%-7.78%

Theravance Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TBPH
Theravance Biopharma
1.5483 of 5 stars
$17.03
flat
$19.00
+11.6%
N/A$884.18M$104.31M16.86110
ARQT
Arcutis Biotherapeutics
4.1781 of 5 stars
$27.31
+4.2%
$39.75
+45.6%
+13.0%$3.42B$376.07M129.76354
INDV
Indivior
4.1637 of 5 stars
$28.21
+0.2%
$46.40
+64.5%
-7.5%$3.33B$1.37B7.88827
SUPN
Supernus Pharmaceuticals
4.1649 of 5 stars
$27.77
+0.5%
$60.20
+116.8%
-34.0%$3.28B$1.24B7.76827
BHC
Bausch Health Cos
2.9049 of 5 stars
$8.30
-1.3%
$8.25
-0.5%
+33.1%$3.10B$10.27BN/A20,300

Related Companies and Tools


This page (NASDAQ:TBPH) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners